Skip to main content

Advertisement

SpringerLink
Log in

Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients

  • Pharmacokinetics and Disposition
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Background

The marketing of sumatriptan, a selective serotonin (5-HT) 1B/1D agonist, first of the class of triptans, has increased the therapeutic options for the treatment of migraine attacks. However, almost one third of patients in clinical trials fail to have headache relief after oral administration of sumatriptan.

Objective

To evaluate whether the interindividual differences in the clinical response following oral administration of sumatriptan are due to differences in its pharmacokinetics.

Methods

We compared the pharmacokinetics of sumatriptan after oral (100 mg) and subcutaneous (6 mg) administration in two age- and gender-matched groups: ten subjects (group A) with satisfactory response and ten (group B) with unsatisfactory response to oral sumatriptan. Patients were studied during headache-free intervals. Blood samples were taken serially from baseline to 360 min after oral administration and from baseline to 180 min after subcutaneous injection. Sumatriptan plasma concentrations were determined by high-performance liquid chromatography (HPLC) with an electrochemical detector.

Results

Following oral dosing, patients of group A absorbed sumatriptan significantly faster and achieved early plasma levels significantly higher than patients of group B. The systemic exposure to sumatriptan during the first 2 h, which are the most important for rapid onset of action and for antimigraine efficacy, was significantly greater in group A than in group B (P < 0.001, Student’s t test for independent data). On the other hand, after subcutaneous injection of sumatriptan, the profile of the curves was similar in all patients, and there were no differences in pharmacokinetics between group A and group B.

Conclusion

The slow rate and low extent of absorption of the drug during the first 2 h after dosing observed in patients of group B could explain their unsatisfactory response to oral sumatriptan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine-current understanding and treatment. N Engl J Med 346(4):257–270

    Article  PubMed  CAS  Google Scholar 

  2. Dodick DW (2005) Triptan nonresponder studies: implications for clinical practice. Headache 45(2):156–162

    Article  PubMed  Google Scholar 

  3. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352(21):2211–2221

    Article  PubMed  CAS  Google Scholar 

  4. Freidank-Mueschenborn E, Fox AW (2005) Resolution of concentration-response differences in onset of effect between subcutaneous and oral sumatriptan. Headache 45(6):632–637

    Article  PubMed  Google Scholar 

  5. Fowler PA, Thomas M, Lacey LF, Andrew P, Dallas FA (1989) Early studies with the novel 5-HT 1-like agonist GR43175 in healthy volunteers. Cephalalgia 9(Suppl 9):57–62

    PubMed  Google Scholar 

  6. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS (1991) The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 31(5):291–294

    Article  PubMed  CAS  Google Scholar 

  7. Scott AK (1994) Sumatriptan clinical pharmacokinetics. Clin Pharmacokinet 27(5):337–344

    Article  PubMed  CAS  Google Scholar 

  8. Lacey LF, Hussey EK, Fowler PA (1995) Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 47(6):543–548

    Article  PubMed  CAS  Google Scholar 

  9. Duquesnoy C, Mamet JP, Sumner D, Fuseau E (1998) Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 6(2):99–104

    Article  PubMed  CAS  Google Scholar 

  10. Fox AW (2004) Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation. Headache 44(2):142–147

    Article  PubMed  Google Scholar 

  11. Ahn AH, Basbaum AI (2005) Where do triptans act in the treatment of migraine? Pain 115(1–2):1–4

    Article  PubMed  Google Scholar 

  12. Burstein R, Jakubowski M (2005) Implications of multimechanism therapy: when to treat. Neurology 64(10 Suppl 2):S16–S20

    PubMed  Google Scholar 

  13. Burstein R, Jakubowski M, Collins B (2004) Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 55(1):19–26

    Article  PubMed  CAS  Google Scholar 

  14. Cady R, Martin V, Mauskop A, Rodgers A, Hustad C, Ramsey K, Skobieranda F (2007) Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia 27(9):1055–1060

    Article  PubMed  CAS  Google Scholar 

  15. D’Amico D, Moschiano F, Bussone G (2006) Early treatment of migraine attacks with triptans: a strategy to enhance outcomes and patient satisfaction? Expert Rev Neurother 6(7):1087–1097

    Article  PubMed  CAS  Google Scholar 

  16. Goadsby PJ (2005) Migraine, allodynia, sensitization and all of that... Eur Neurol 53(Suppl 1):10–16

    Article  PubMed  Google Scholar 

  17. Landy SH, McGinnis JE, McDonald SA (2007) Clarification of developing and established clinical allodynia and pain-free outcomes. Headache 47(2):247–252

    Article  PubMed  Google Scholar 

  18. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD (2003) The triptan formulations : how to match patients and products. CNS Drugs 17(6):431–447

    Article  PubMed  CAS  Google Scholar 

  19. Walls C, Lewis A, Bullman J, Boswell D, Summers SJ, Dow A, Sidhu J (2004) Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr Med Res Opin 20(6):803–809

    Article  PubMed  CAS  Google Scholar 

  20. Headache Classification Subcommittee of the International Headache Society (2004) The international classification of headache disorders, 2nd edn. Cephalalgia 24(Suppl 1):S9–S160

    Google Scholar 

  21. Ferrari A, Sternieri E, Ferraris E, Bertolini A (2003) Emerging problems in the pharmacology of migraine: interactions between triptans and drugs for prophylaxis. Pharmacol Res 48(1):1–9

    PubMed  CAS  Google Scholar 

  22. Dunne M, Andrew P (1996) Fully automated assay for the determination of sumatriptan in human serum using solid-phase extraction and high-performance liquid chromatography with electrochemical detection. J Pharm Biomed Anal 14(6):721–726

    Article  PubMed  CAS  Google Scholar 

  23. Lacey LF, Keene ON, Duquesnoy C, Bye A (1994) Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies. J Pharm Sci 83(2):212–215

    Article  PubMed  CAS  Google Scholar 

  24. Normann G, Streiner D (2000) Biostatistics. The bare essentials, 2nd edn. B.C. Decker Inc., Ontario, Canada, pp 1–162

    Google Scholar 

  25. Plosker GL, McTawish D (1994) Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 47(4):622–651

    Article  PubMed  CAS  Google Scholar 

  26. Dahlof CG (2001) Sumatriptan: pharmacological basis and clinical results. Curr Med Res Opin 17(Suppl 1):s35–s45

    Article  PubMed  Google Scholar 

  27. Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D (2004) Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: results of a multicenter, randomized, placebo-controlled study. Clin Ther 26(2):214–223

    Article  PubMed  CAS  Google Scholar 

  28. Barbanti P, Le Pera D, Cruccu G (2007) Sumatriptan fast-disintegrating/rapid-release tablets in the acute treatment of migraine. Expert Rev Neurother 7(8):927–934

    Article  PubMed  CAS  Google Scholar 

  29. Sheftell FD, Dahlof CG, Brandes JL, Agosti R, Jones MW, Barrett PS (2005) Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 27(4):407–417

    Article  PubMed  CAS  Google Scholar 

  30. Cady RK, Sheftell F, Lipton RB, O’Quinn S, Jones M, Putnam DG, Crisp A, Metz A, McNeal S (2000) Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 22(9):1035–1048

    Article  PubMed  CAS  Google Scholar 

  31. Linde M, Mellberg A, Dahlof C (2006) Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 26(2):113–121

    Article  PubMed  CAS  Google Scholar 

  32. Geraud G, Keywood C, Senard JM (2003) Headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 43(4):376–388

    Article  PubMed  Google Scholar 

  33. Maas HJ, Danhof M, Della Pasqua OE (2006) Prediction of headache response in migraine treatment. Cephalalgia 26(4):416–422

    Article  PubMed  CAS  Google Scholar 

  34. Visser WH, Burggraaf J, Muller LM, Schoemaker RC, Fowler PA, Cohen AF, Ferrari MD (1996) Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. Clin Pharmacol Ther 60(4):452–460

    Article  PubMed  CAS  Google Scholar 

  35. Sternieri E, Pinetti D, Coccia CP, Leone S, Bertolini A, Ferrari A (2005) Pharmacokinetics of sumatriptan in non-respondent and in adverse drug reaction reporting migraine patients. J Headache Pain 6(4):319–321

    Article  PubMed  CAS  Google Scholar 

  36. Visser WH, de Vriend RH, Jaspers NH, Ferrari MD (1996) Sumatriptan non responders: a survey in 366 migraine patients. 36(8):471–475

  37. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr (1991) Treatment of acute migraine with subcutaneous sumatriptan. JAMA 265(21):2831–2835

    Article  PubMed  CAS  Google Scholar 

  38. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294):1668–1675

    Article  PubMed  CAS  Google Scholar 

  39. Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60(6):1259–1287

    Article  PubMed  CAS  Google Scholar 

  40. Winner P, Adelman J, Aurora S, Lener ME, Ames M (2006) Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: two multicenter, prospective, randomized, double-blind, controlled studies in adults. Clin Ther 28(10):1582–1591

    Article  PubMed  CAS  Google Scholar 

  41. Dahlöf CG, Lipton RB, McCarroll KA, Kramer MS, Lines CR, Ferrari MD (2000) Within-patient consistency of response of rizatriptan for treating migraine. Neurology 55(10):1511–1516

    PubMed  Google Scholar 

  42. Tfelt-Hansen P (2007) Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment. J Headache Pain 8(5):273–276, Online DOI 10.1007/s10194-007-0411-x

  43. The Oral Sumatriptan Dose-Defining Study Group (1991) Sumatriptan-an oral dose-defining study. Eur Neurol 31(5):300–305

    Article  Google Scholar 

  44. Cutler NR, Hussey EK, Sramek JJ, Clements BD, Paulsgrove LA, Busch MA, Donn KH (1991) Oral sumatriptan in pharmacokinetics in the migranous state. Cephalalgia 11(Suppl 11):222–223

    Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Division of Toxicology and Clinical Pharmacology, Headache Centre, University Centre for Adaptive Disorders and Headache, Section Modena II, University of Modena and Reggio Emilia, Modena, Italy

    Anna Ferrari, Diego Pinetti, Alfio Bertolini, Ciro Coccia & Emilio Sternieri

  2. Division of Toxicology and Clinical Pharmacology, Headache Centre, University of Modena and Reggio Emilia, Policlinico, Largo del Pozzo, 71-41100, Modena, Italy

    Anna Ferrari

Authors
  1. Anna Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diego Pinetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alfio Bertolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ciro Coccia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Emilio Sternieri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anna Ferrari.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ferrari, A., Pinetti, D., Bertolini, A. et al. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients. Eur J Clin Pharmacol 64, 489–495 (2008). https://doi.org/10.1007/s00228-007-0443-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0443-9

Keywords

Search

Navigation